Spero Therapeutics (NASDAQ:SPRO) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Spero Therapeutics (NASDAQ:SPRO) from a hold rating to a sell rating in a research note published on Saturday morning,Wall Street Zen reports.

A number of other research analysts also recently weighed in on SPRO. Weiss Ratings downgraded shares of Spero Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, October 26th. Compass Point upgraded Spero Therapeutics to a “neutral” rating in a research report on Monday, September 14th. Zacks Research upgraded Spero Therapeutics to a “hold” rating in a research note on Monday, September 14th. Cantor Fitzgerald started coverage on Spero Therapeutics in a research note on Wednesday, October 28th. They issued an “overweight” rating and a $6.00 price target for the company. Finally, HC Wainwright upped their price target on Spero Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Monday, September 14th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $6.00.

Spero Therapeutics Price Performance

NASDAQ:SPRO opened at $1.04 on Friday. The firm has a market cap of $60.57 million, a price-to-earnings ratio of 10.64 and a beta of 1.50. The company has a 50 day moving average price of $1.17 and a 200-day moving average price of $1.98. Spero Therapeutics has a 1-year low of $1.03 and a 1-year high of $3.08.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. Spero Therapeutics had a net margin of 24.90% and a return on equity of 16.17%. On average, sell-side analysts anticipate that Spero Therapeutics will post -0.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Spero Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Susquehanna Fundamental Investments LLC purchased a new position in Spero Therapeutics during the second quarter valued at $36,000. Global Retirement Partners LLC purchased a new stake in shares of Spero Therapeutics during the second quarter worth about $55,000. GSA Capital Partners LLP purchased a new stake in shares of Spero Therapeutics during the second quarter worth about $632,000. BlackRock Inc. purchased a new stake in shares of Spero Therapeutics during the second quarter worth about $1,314,000. Finally, Alphabet Inc. acquired a new position in shares of Spero Therapeutics during the 2nd quarter worth about $1,967,000. 25.60% of the stock is currently owned by institutional investors and hedge funds.

About Spero Therapeutics

Spero Therapeutics, Inc (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens.

Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.